Literature DB >> 7654466

Anticalcification and antiresorption effects of bisacylphosphonates.

J M Van Gelder1, E Breuer, A Ornoy, A Schlossman, N Patlas, G Golomb.   

Abstract

Some geminal bisphosphonates are used clinically in a number of important bone and calcium-related diseases. This work reports the anticalcification and antiresorption effects of a series of bisacylphosphonates, nongeminal compounds with varying chain lengths having oxo groups in alpha positions relative to the phosphonic functions. We compared the activity of the novel compounds to clinically used geminal bisphosphonates, and to a bisphosphonate devoid of the oxo groups. The interaction of the compounds with calcium was studied by various in vitro and in vivo models. We found that keto groups in alpha positions to the phosphonic functions render activity. The bisacylphosphonates with a shorter chain [(CH2)n, = 4, 6] were found significantly to inhibit hydroxyapatite formation and dissolution in vitro, the calcification of bioprosthetic tissue implanted subdermally in rats, and bone resorption in the intact young animal model. The various in vitro results were found to be in good correlation with the in vivo results. Structure-activity relationship studies indicate that both bisacylphosphonates and geminal bisphosphonates are active only when at least three ionizable groups are present in the molecule. The role of the keto groups is related to their contribution to chelating calcium and/or to their electron-withdrawing influence on acidity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7654466     DOI: 10.1016/8756-3282(95)00081-n

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  7 in total

Review 1.  The presentation, assessment, pathogenesis, and treatment of calcinosis in juvenile dermatomyositis.

Authors:  Mark F Hoeltzel; Edward J Oberle; Angela Byun Robinson; Arunima Agarwal; Lisa G Rider
Journal:  Curr Rheumatol Rep       Date:  2014-12       Impact factor: 4.592

2.  Bisphosphonates and tetracycline: experimental models for their evaluation in calcium-related disorders.

Authors:  H Cohen; V Solomon; I S Alferiev; E Breuer; A Ornoy; N Patlas; N Eidelman; G Hägele; G Golomb
Journal:  Pharm Res       Date:  1998-04       Impact factor: 4.200

3.  Synthesis and preclinical pharmacology of 2-(2-aminopyrimidinio) ethylidene-1,1-bisphosphonic acid betaine (ISA-13-1)-a novel bisphosphonate.

Authors:  H Cohen; I S Alferiev; J Mönkkönen; M J Seibel; T Pinto; A Ezra; V Solomon; D Stepensky; H Sagi; A Ornoy; N Patlas; G Hägele; A Hoffman; E Breuer; G Golomb
Journal:  Pharm Res       Date:  1999-09       Impact factor: 4.200

4.  In vitro inhibition of membrane-mediated calcification by novel phosphonates.

Authors:  D Skrtic; N Eidelman; G Golomb; E Breuer; E D Eanes
Journal:  Calcif Tissue Int       Date:  1996-05       Impact factor: 4.333

5.  Calcinosis in juvenile dermatomyositis: frequency, risk factors and outcome.

Authors:  Isha Saini; Mani Kalaivani; Sushil Kumar Kabra
Journal:  Rheumatol Int       Date:  2016-03-23       Impact factor: 2.631

6.  Preparation of mixed trialkyl alkylcarbonate derivatives of etidronic acid via an unusual route.

Authors:  Petri A Turhanen; Janne Weisell; Jouko J Vepsäläinen
Journal:  Beilstein J Org Chem       Date:  2012-11-20       Impact factor: 2.883

7.  Unexpected degradation of the bisphosphonate P-C-P bridge under mild conditions.

Authors:  Petri A Turhanen; Jouko J Vepsäläinen
Journal:  Beilstein J Org Chem       Date:  2008-01-21       Impact factor: 2.883

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.